AstraZeneca PLC (AZN)
After hours:
| Previous Close | 65.99 |
| Open | 65.40 |
| Bid | 65.56 x 1800 |
| Ask | 65.52 x 1100 |
| Day's Range | 65.19 - 65.78 |
| 52 Week Range | 52.65 - 72.12 |
| Volume | |
| Avg. Volume | 5,055,911 |
| Market Cap | 203.117B |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 102.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.45 (2.18%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | N/A |
- Business Wire
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
WILMINGTON, Del., January 23, 2023--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product. On 9 January 2023, AstraZeneca announced that it had entered into a definitive agreement to acquire CinCor. Following the successful closing of the
- GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS® (savolitinib) has been included in the updated National Reimbursement Drug List (“NRDL”) for the treatment of locally advanced or metastatic non-small cell lung cancer (“NSCLC”) adult patients with MET exon 14-skipping alterations who
- Business Wire
AIRSUPRA™ (PT027) approved in the US for asthma
WILMINGTON, Del., January 11, 2023--AIRSUPRA™ (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
